Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Anti-TNF Refractory Radiographic AxSpA
NCT02438787Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of ustekinumab in ankylosing spondylitis (AS), sponsored by Janssen Pharmaceutical. Started Jul 2015; status: terminated.
02
Drugs
ustekinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02438787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438787.